{
    "clinical_study": {
        "@rank": "19990", 
        "acronym": "SCIG03", 
        "arm_group": {
            "arm_group_label": "Subgam-VF", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The main objective of the study is to determine the pharmacokinetics profile of Subgam-VF.\n      The secondary objectives are to assess the safety of Subgam-VF and refine the dose\n      adjustment coefficient for Subgam-VF needed for subjects switching from prior intravenous\n      immunoglobulin (IGIV) therapy."
        }, 
        "brief_title": "Pharmacokinetics (PK) and Safety of Subgam\u00aeVF in Primary Immunodeficiency Diseases", 
        "condition": [
            "Primary Immune Deficiency Disorders", 
            "Common Variable Immunodeficiency", 
            "X-linked Agammaglobulinaemia", 
            "Hyper-Immunoglobulin M (IgM0Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Agammaglobulinemia", 
                "Common Variable Immunodeficiency", 
                "Immunologic Deficiency Syndromes", 
                "Genetic Diseases, X-Linked"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Aged between 2 and 75 years.\n\n          2. Diagnosed with primary immunodeficiency disease e.g. common variable\n             immunodeficiency, X-linked and autosomal forms of agammaglobulinaemia, hyper-IgM\n             syndrome.\n\n          3. Currently receiving a licensed IGIV at a dose that has not changed by \u00b1 50% of the\n             mean dose for at least three months before study entry (Visit 1) and\n\n               1. Dose is between 300 and 800 mg/kg/infusion.\n\n               2. The infusion interval is between 21 and 28 days inclusive for IGIV.\n\n               3. Has maintained a trough level of \u2265 5 g/L (500 mg/dL) for the last three months\n                  before Visit 1.\n\n          4. Female subjects who are (or become) sexually active must practice contraception by\n             using a method of proven reliability for the duration of the study.\n\n          5. Females of child-bearing potential must have a negative result on an human chorionic\n             gonadotropin (HCG)-based pregnancy test.\n\n          6. Willing to comply with all aspects of the protocol for the duration of the study.\n\n          7. Signed an informed consent form. In the case of subjects under the legal age the\n             parent/guardian will sign an informed consent form and where appropriate the subject\n             will sign an assent form.\n\n        Exclusion Criteria:\n\n          1. Is currently using subcutaneous IgG (SCIG).\n\n          2. Has a history of any severe anaphylactic reaction to blood or any blood-derived\n             product.\n\n          3. Has selective IgA deficiency, history of reaction to products containing IgA, or has\n             a history of antibodies to immunoglobulin A (IgA).\n\n          4. Has impaired cellular or innate immunity (i.e. only subjects with impaired humoral\n             immunity to be included)\n\n          5. Has evidence of an active infection at the time of enrolment.\n\n          6. Has previously completed or withdrawn from this study.\n\n          7. Is currently receiving, or has received, any investigational agent within the prior\n             three months.\n\n          8. Is pregnant (confirmed by a positive result on an HCG-based pregnancy test) or is\n             nursing.\n\n          9. Is positive for any of the following at screening:\n\n               -  Serological test for Human Immunodeficiency Virus (HIV) 1&2, hepatitis C virus\n                  (HCV), or Hepatitis B Surface Antigen (HBsAg)\n\n               -  Nucleic acid Amplification Test [Polymerase Chain Reaction - PCR] (NAT) for HCV\n\n               -  NAT for HIV\n\n         10. Has levels at screening greater than 2.5 times the upper limit of normal as defined\n             at the central laboratory of any of the following:\n\n               -  Alanine transaminase (ALT)\n\n               -  Aspartate transaminase (AST)\n\n         11. Has severe renal impairment (defined as serum creatinine greater than two times the\n             upper limit of normal or blood urea nitrogen (BUN) greater than 2.5 times the upper\n             limit of normal for the range of the laboratory doing the analysis); the subject is\n             on dialysis; or has a history of acute renal failure.\n\n         12. Is known to abuse alcohol, opiates, psychotropic agents, or other chemicals or drugs,\n             or has done so within the past 12 months.\n\n         13. Has a history of deep vein thrombosis (DVT), or thrombotic complications of IGIV\n             therapy.\n\n         14. Suffers from any acute or chronic medical condition, (e.g. renal disease or\n             predisposing conditions for renal disease, coronary artery disease, or protein losing\n             state, proteinuria) that the investigator feels may interfere with the conduct of the\n             study.\n\n         15. Has an acquired medical condition, such as chronic lymphocytic leukemia, lymphoma,\n             multiple myeloma, chronic or recurrent neutropenia (ANC < 1000 x 109/L).\n\n         16. Is receiving the following medication:\n\n               -  Steroids (long-term daily, > 0.15 mg of prednisone equivalent/kg/day).\n                  Requirement for short or intermittent courses would not exclude a subject.\n\n               -  Immunosuppressive drugs\n\n               -  Immunomodulatory drugs\n\n         17. Has non-controlled arterial hypertension (systolic blood pressure > 160 mmHg and/or\n             diastolic blood pressure > 100 mmHg).\n\n         18. Has anemia (hemoglobin < 10 g/dL) at screening.\n\n         19. Has severe dermatitis that would preclude sites for safe product administration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884311", 
            "org_study_id": "SCIG03"
        }, 
        "intervention": {
            "arm_group_label": "Subgam-VF", 
            "description": "Subgam-VF dose will be given as 1.45 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.", 
            "intervention_name": "Subgam", 
            "intervention_type": "Biological", 
            "other_name": "Subgam-VF"
        }, 
        "intervention_browse": {
            "mesh_term": "Immunoglobulins"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Primary Immune Deficiency Disorders", 
            "Common Variable Immunodeficiency", 
            "X-linked agammaglobulinaemia", 
            "Hyper-IgM Syndrome", 
            "Subcutaneous", 
            "Immunoglobulins"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subgam\u00aeVF in Primary Immunodeficiency Diseases", 
        "overall_official": {
            "affiliation": "Bio Products Laboratory Limited", 
            "last_name": "Tim J. Aldwinckle, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determine the PK profile of Subgam-VF and compare the Area under the curve  to a given treatment period (AUC [0-t)]) with historical data all standardized to 1 week at steady state from Gammaplex 5% IGIV Primary Immune studies (GMX01 and GMX04)", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884311"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events:\tNumber and percent of infusions associated with 1 or more AEs during the study and specifically AEs that begin during the infusion or within 72 hours after completion of the infusion.", 
                "measure": "Assess the safety of Subgam-VF including the incidence of adverse events (AEs) and site infusion reactions in subjects with primary immunodeficiency", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Refine the dose adjustment coefficient for Subgam-VF", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }
        ], 
        "source": "Bio Products Laboratory", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bio Products Laboratory", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2015", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014", 
        "why_stopped": "Study suspended pending advice from the FDA"
    }
}